Today on in-pharmatechnologist.com   Mega deal creates largest pharma player in CEE Pharmaceutical manufacturing: news in brief J&J rejigs Extra breathing space for epinephrine MDI ban Icahn invests in Genzyme, prompts takeover rumours

Related Industry News   Celesio sees profits drag Stem cell breakthrough avoids the embryo controversy Preclinical services news in brief Targeted lupus treatment on the horizon

Breaking News on Pharmaceutical Technology
Daily  Friday 16 November 2007		Forward to a colleague

	Sponsored Link Why outsource GMP audits? Outsourcing GMP audits can help harmonize quality compliance within supply chains. These audit solutions can be provided in a globally consistent and independent manner while appreciating the cultural and regulatory differences. Join FREE webinar for more... Click Here Access Full Stories Mega deal creates largest pharma player in CEE Hungarian pharma Gedeon Richter has announced plans to combine with Polish firm Polpharma to create a major presence in Central Eastern Europe (CEE) through a share deal worth HUF231bn ($1.3bn)... Read Pharmaceutical manufacturing: news in brief In-PharmaTechnologist.com brings you a selection of recent headlines from around the pharmaceutical manufacturing industry... Read J&J rejigs Johnson & Johnson (J&J) has announced plans to revamp its organisation in a bid to address the "new environment" emerging in human healthcare... Read Extra breathing space for epinephrine MDI ban The US Food and Drug Administration (FDA) has given stakeholders an extra month to get their views in on scrapping epinephrine inhalers containing CFCs... Read Icahn invests in Genzyme, prompts takeover rumours The man often credited with causing Biogen Idec to be put up for sale, billionaire corporate raider Carl Icahn, has invested in Genzyme and promptly started industry tongues wagging about a takeover... Read
	All News Headlines for: November | October | September
	Product Brochure Advanced Chiral Chromatography DAICEL announce the launch of CHIRALPAK® IC. The combination of CHIRALPAK® IA, IB and now IC provides a screening set of column with exceptionally high success rates. The chiral separation of > 99% of all small molecules is attained using just 3 columns and four... Click Here
	Related Industry News Celesio sees profits drag Celesio fingerpointed two 'extraordinary items' in its dominant Wholesale division for the drag on company profits during the third quarter... Read Stem cell breakthrough avoids the embryo controversy US researchers have developed a way of creating primate embryonic stem cells that avoids the need to use fertilised embryos, potentially leading to more ethical ways of curing degenerative diseases... Read Preclinical services news in brief In this week's review of activity within the preclinical research services arena, news has emerged involving GATC Biotech, NextGen Sciences and Genedata... Read Targeted lupus treatment on the horizon Researchers have uncovered some of the underlying causes of lupus, and have even suggested certain targeted therapies to tackle the autoimmune disease... Read Weekly Comment Pharma must 'reinvent' itself to survive With IMS Health's annual forecast for the pharma industry predicting slower approvals, more black box warnings and the continuation of the 'wave of genericization,' the shift by pharma firms to refocus and reinvent themselves will need to move on apace in order to secure their position in a changing market. Read Technical / White Paper Sensitive and selective with IC-MS coupling The combination of a highly efficient ion chromatograph with a high-resolution mass spectrometer represents a modern detection technique whose strengths lie in its extreme sensitivity and excellent selectivity. IC-MS coupling is also used when matrix effects have to be... Click Here Previous Headlines AMRI continues growth Albany Molecular Research Inc (AMRI) recently turned in Q3 results, posting figures buoyed by continued demand for its pharmaceutical development services... Read Pfizer, Nektar agreement not so sweet after all? Pfizer yesterday announced a multi-million dollar pay-off to ex-partner Nektar Therapeutics, but the details of the deal reveal not only Nektar's concerns for its future, but also that Pfizer is still keeping its... Read Pharmaceutical manufacturing: people on the move AstraZeneca, Cumberland Pharmaceuticals, Pieris, Theraptosis and InteKrin Therapeutics have all had people on the move in the world of pharmaceutical manufacturing... Read NPIL to trim ex-Pfizer site NPIL Pharma last week told workers at its former Pfizer plant in Morpeth, UK that the company is considering hiving off jobs in a bid to maintain the site's viability... Read AstraZeneca in 'serious trouble', say analysts An analyst report released yesterday identified AstraZeneca as being in 'serious trouble' and branded it as potentially the 'worst [large cap] performer in [the] entire sector' over the next eight years... Read Product Information - brochures, Web centers The Safe'n'Sound Passive Safety Device for Prefilled Syringes - Product Presentation A Review of Dissolution tests with the Flow Through Method - Application Notes Product Innovation Alerts - Free of Charge Indicate your research interests and receive alerts on relevant products and market innovations Cleanroom, safety equipment, supplies Contract services (outsourcing) Drug delivery systems Ingredients, excipients and raw materials IT solutions Lab equipment & consumables Packaging machinery & supplies Processing (automation, control, separation...) QA/QC & validation Tabletting, coating & ancillary equipment

	Free Newsletters for Pharmaceuticals Access now !Choose from over 20 industry e-newsletters Access Decision News Media e-newsletters for the food, beverage & nutrition industries, click here
	Forward to a colleague

	To continue to receive this newsletter in your inbox, please add newsletter@In-PharmaTechnologist.com to your address book
	Update preferences | Change your email address | Unsubscribe
	Contact us: Advertising | Recruitment | Privacy policy | Terms & conditions | Feedback
	© 2007 - Decision News Media S.A.S - All Rights Reserved Le Belem - 355, rue Vendemiaire - 34000 Montpellier - France http://www.decisionnewsmedia.com